Literature DB >> 17978819

Mechanisms of Disease: HCV-induced liver injury.

John A Mengshol1, Lucy Golden-Mason, Hugo R Rosen.   

Abstract

HCV persistently infects the majority of patients exposed to it and can cause irreversible fibrosis, leading to the onerous clinical sequelae of cirrhosis. In this Review, we discuss the direct effects of HCV on hepatocytes and the role of the immune system in liver damage. HCV, like many viruses, has developed methods by which to subvert host innate and adaptive immune responses to infection. HCV proteins seem to modulate apoptosis and steatosis, ultimately leading to hepatic stellate cell activation, fibrosis and hepatocellular carcinoma. In addition, HCV manipulates the immune system, disrupting both innate and adaptive immunity to establish persistent infection. The immune system initially attempts to eradicate the virus, but, in the setting of chronic infection, probably promotes hepatocyte damage and fibrosis through direct cellular toxicity and the release of inflammatory cytokines. Multiple types of cytotoxic lymphocytes, comprising the unique immune hepatic microenvironment, are likely to be important in the pathogenesis of HCV-induced liver damage. The net liver damage from HCV infection depends on the balance between the host's antiviral mechanisms and the virus' ability to subvert them.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978819     DOI: 10.1038/ncpgasthep0961

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  42 in total

1.  Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells.

Authors:  Vania Bonifaz; Ying Shan; Richard W Lambrecht; Susan E Donohue; Darcy Moschenross; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

Review 2.  microRNAs: fad or future of liver disease.

Authors:  Ashley M Lakner; Herbert L Bonkovsky; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

3.  A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection.

Authors:  John A Mengshol; Lucy Golden-Mason; Tomohiro Arikawa; Maxwell Smith; Toshiro Niki; Ryan McWilliams; Jessica A Randall; Rachel McMahan; Michael A Zimmerman; Manu Rangachari; Evgenia Dobrinskikh; Pierre Busson; Stephen J Polyak; Mitsuomi Hirashima; Hugo R Rosen
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

4.  Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Authors:  K Yanagisawa; S Yue; H J van der Vliet; R Wang; N Alatrakchi; L Golden-Mason; D Schuppan; M J Koziel; H R Rosen; M A Exley
Journal:  J Viral Hepat       Date:  2013-03-11       Impact factor: 3.728

5.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

6.  Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.

Authors:  Dennis J Hartigan-O'Connor; Din Lin; James C Ryan; Valentina A Shvachko; Myrna L Cozen; Mark R Segal; Norah A Terrault; Lewis L Lanier; M Michele Manos; Joseph M McCune
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

7.  Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages.

Authors:  Abdelfattah M Attallah; Sanaa O Abdallah; Mohamed S Albannan; Mohamed M Omran; Ahmed A Attallah; Khaled Farid
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

8.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

Review 9.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

10.  Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers.

Authors:  Xinxia Peng; Yu Li; Kathie-Anne Walters; Elizabeth R Rosenzweig; Sharon L Lederer; Lauri D Aicher; Sean Proll; Michael G Katze
Journal:  BMC Genomics       Date:  2009-08-11       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.